Lexicon Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Lexicon Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Lexicon Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Lexicon Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company focused on discovering and developing precise medicines for serious, chronic conditions. The company's main activities include research and development of innovative drug candidates and the commercialization of approved drugs. Lexicon's major products include INPEFA (sotagliflozin), an oral tablet for heart failure, and drug candidates like pilavapadin for neuropathic pain and LX9851 for obesity. The company serves patients with chronic conditions, particularly in the fields of cardiometabolic and neuropathic pain, through its pharmaceutical offerings. Lexicon collaborates with third-party contract manufacturing organizations for the production and distribution of its products. Lexicon is headquartered in The Woodlands, Texas, the US.
Headquarters
United States of America
Address
2445 Technology Forest Blvd, 11th Floor, The Woodlands, Texas, 77381
Website
www.lexpharma.com
Telephone
1 281 8633000
No of Employees
81
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LXRX (NASD)
Revenue (2024)
$49.8M
60.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
74.9%
(2024 vs 2023)
Market Cap*
$999.4M
Net Profit Margin (2024)
XYZ
84.3%
(2024 vs 2023)
* As of and is in US$
Lexicon Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Pilavapadin |
| SGLT1/2 Inhibitor: Heart Failure | Sotagliflozin |
| SGLT1/2 Inhibitor: Hypertrophic Cardiomyopathy (HCM) | INPEFA |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In March, the company signed a licensing agreement to allow Novo Nordisk to develop, manufacture, and commercialize LX9851 in all indications. |
| 2024 | Regulatory Approval | In December, the company received a response letter from the U.S. Food and Drug Administration for Zynquista (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease. |
| 2024 | Contracts/Agreements | In October, the company signed a licensing agreement to allow Viatris Inc to commercialize sotagliflozin outside of the US and Europe in all indications. |
Competitor Comparison
| Key Parameters | Lexicon Pharmaceuticals Inc | Eli Lilly and Co | AstraZeneca Plc | Bristol-Myers Squibb Co | Boehringer Ingelheim International GmbH |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United States of America | Germany |
| City | The Woodlands | Indianapolis | Cambridge | Princeton | Ingelheim am Rhein |
| State/Province | Texas | Indiana | Cambridgeshire | New Jersey | Rheinland-Pfalz |
| No. of Employees | 81 | 50,605 | 96,100 | 32,500 | 54,300 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael S. Exton, PhD | Director; Chief Executive Officer | Executive Board | 2024 | 56 |
| Scott M. Coiante | Senior Vice President; Chief Financial Officer | Senior Management | 2025 | 59 |
| Craig Granowitz, MD, PhD | Senior Vice President; Chief Medical Officer | Senior Management | 2021 | 61 |
| Raymond Debbane | Chairman | Non Executive Board | 2007 | 71 |
| Brian T. Crum | Senior Vice President; General Counsel | Senior Management | 2021 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer